Issue Date: February 15, 2016 | Web Date: February 11, 2016
Novartis Tags Price Of Heart Drug To Patient Outcomes
Novartis has entered a performance-based pricing pact with U.S. health insurance majors Cigna and Aetna for Entresto, its new congestive heart failure drug. The novel deal is an early foray into crafting payment schemes based on patient outcomes and comes as drug companies are under pressure to lower prices.
Cigna says the deal ties the price of Entresto to how well it improves the health of patients relative to its performance in clinical trials. The . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society